Form 4: Upstream Bio Director Daniella Beckman Granted 17,096 Stock Options

Upstream Bio, Inc. Director Daniella Beckman was granted 17,096 stock options with an exercise price of $11.59, vesting upon continued service.

Summary

• Daniella Beckman, a Director of Upstream Bio, Inc. (UPB), was granted 17,096 stock options.
• The options have an exercise price of $11.59 per share.
• The grant date for these options was June 10, 2025.
• The options will vest upon the earlier of June 10, 2026, or the date of the next Annual Meeting of Stockholders, contingent on Ms. Beckman's continued service.
• The options expire on June 9, 2035.
• Following this transaction, Ms. Beckman beneficially owns 17,096 derivative securities directly.
• An Exhibit 24.2 Substitute Power of Attorney was filed, indicating that Michael Gray, an attorney-in-fact, appointed Allison Ambrose as a substitute attorney-in-fact to execute SEC filings for several individuals, including Daniella Beckman, effective December 19, 2024.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal as it aligns interests and incentivizes long-term performance, reflecting confidence in the company's future. It's a routine compensation event, not a major strategic announcement, hence a moderately positive score.

Positives

• The granting of stock options to a director aligns their interests with shareholders, incentivizing long-term performance and value creation.
• The options have a long expiration date of June 9, 2035, providing ample time for potential stock price appreciation and value realization.

Negatives

• The value of the options is contingent on the company's stock price appreciating above the $11.59 exercise price, meaning there is no immediate cash benefit to the director.
• Future exercise of these options could lead to minor dilution for existing shareholders, although this is a standard aspect of equity compensation.

Risks

• The value of the stock options is directly tied to the future performance of Upstream Bio's stock price; if the stock price does not exceed the exercise price of $11.59, the options may expire worthless.
• Vesting of the options is subject to Daniella Beckman's continued service to the company, meaning the options could be forfeited if her service terminates before the vesting conditions are met.

Future Outlook

The grant of stock options with a future vesting schedule indicates an expectation of continued service from the director and aligns her incentives with the long-term growth and stock performance of Upstream Bio, Inc.

Management Comments

• "The shares underlying this option shall vest upon the earlier of (i) June 10, 2026 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date."

Industry Context

Equity compensation, such as stock option grants, is a common and widely accepted practice in the biotechnology and pharmaceutical industries. It serves as a key mechanism to attract, retain, and incentivize highly qualified personnel, including directors, by aligning their financial interests directly with the company's long-term success and shareholder value creation. This approach is particularly prevalent in growth-oriented sectors like biotech, where companies often prioritize R&D and may use equity to conserve cash while still offering competitive compensation.

Comparison to Industry Standards

• The granting of stock options to directors is a standard component of compensation packages across publicly traded companies, especially within the biotech sector.
• To fully assess the competitiveness and appropriateness of this grant, it would typically be compared against director compensation practices at peer companies of similar market capitalization, stage of development, and industry focus. Without specific peer data, a direct quantitative comparison is not feasible, but the compensation mechanism itself is consistent with industry norms.

Corporate Governance

Stakeholder Impact

• **Shareholders:** The grant of stock options aligns the director's financial interests with those of shareholders, potentially leading to enhanced long-term performance and shareholder value. However, future exercise of these options could result in minor share dilution.
• **Employees:** There is no direct impact on the general employee base, but this action reinforces the company's compensation philosophy for key leadership roles.

Next Steps

• Daniella Beckman's stock options will vest upon the earlier of June 10, 2026, or the date of the next Annual Meeting of Stockholders, subject to her continued service.
• Upstream Bio, Inc. will continue to file Form 4s for any future changes in beneficial ownership by its insiders as required by SEC regulations.

Key Dates

Recommendation

Keywords

Upstream Bio, UPB, Stock Option, Form 4, Insider Transaction, Equity Compensation, Director Compensation, Beneficial Ownership, SEC Filing, Biotechnology